Clinical review report Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults.
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281406719 |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (63 pages)) : illustrations |
